Clinical Evidence on iTind: Explore the Latest Research Findings

Discover the latest and most relevant clinical evidence on iTind, a minimally invasive treatment for Benign Prostatic Hyperplasia (BPH), through our curated list of research findings. This page serves as a resource for researchers, clinicians, and healthcare professionals interested in staying informed about the efficacy and impact of iTind in relieving the symptoms of BPH. Each entry includes a link to the abstract for further reading.

NEW:
I-Tind for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Mid-term outcomes from a multicenter cohort

Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results

Temporarily implanted nitinol device versus prostatic urethral lift for minimally invasive surgical treatment of benign prostatic hyperplasia with lower urinary tract symptoms: a matching-adjusted indirect comparison

3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction

Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study

The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial

Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study

Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up

The information on this page was last updated on July 4^th, 2025.